



Kenvue Inc. (KVUE)

Updated December 1st, 2025 by Nathan Parsh

Key Metrics

Current Price:	\$17.35	5 Year Annual Expected Total Return:	4.1%	Market Cap:	\$33 B
Fair Value Price:	\$14.42	5 Year Growth Estimate:	3.0%	Ex-Dividend Date:	02/13/26 ¹
% Fair Value:	120%	5 Year Valuation Multiple Estimate:	-3.6%	Dividend Payment Date:	02/27/26 ²
Dividend Yield:	4.8%	5 Year Price Target	\$17	Years Of Dividend Growth:	63
Dividend Risk Score:	B	Sector:	Health Care	Rating:	Hold

Overview & Current Events

On May 4th, 2023, Johnson & Johnson (JNJ) completed its split off of its consumer healthcare group, called Kenvue Inc. Kenvue has three segments, including Self Care, Skin Health and Beauty, and Essential Health. Self-Care's product portfolio includes cough, cold, allergy, smoking cessation, and pain care products among others. Skin Health and Beauty holds products such as face, body, hair, and sun care. Essential Health contains products for women's health, wound care, oral care, and baby care. Well-known brands in Kenvue's product line up include Tylenol, Listerine, Band-Aid, Neutrogena, Nicorette, and Zyrtec. These businesses contributed approximately 17% of Johnson & Johnson's annual revenue. While Kenvue is a new, standalone business, it carries Johnson & Johnson's 60+ year dividend increase streak.

On July 30th, 2025, Kenvue announced that it was raising its quarterly dividend 1.2% to \$0.2075.

On November 3rd, 2025, it was announced that Kimberly-Clark Corporation (KMB) had agreed to purchase Kenvue. The enterprise value of the acquisition is \$48.7 billion. Shareholders will receive \$3.50 in cash and 0.14625 shares of Kimberly-Clark stock for each Kenvue share that they own. This works out to a total value of \$21.01 per Kenvue share based on the closing price of KMB on October 31st, 2025. The deal is expected to close in the second half of 2026.

That same day, Kenvue reported third quarter results for the period ending September 28th, 2025. For the quarter, revenue decreased 3.5% to \$3.76 billion, which was \$60 million below estimates. Adjusted earnings-per-share of \$0.28 matched last year's results and was \$0.02 better than expected.

Organic sales were lower by 4.4% for the quarter while currency exchange acted as a 1.0% tailwind to results. For the quarter, volume fell 4.0% and unfavorable value realization lowered results by 0.4%. Organic revenue for Self-Care decreased 5.3%, Skin Health and Beauty fell 3.5%, and Essential Health was down 4.2%. All three categories saw declines in volume. Gross profit margin expanded 60 basis points to 59.1%.

Kenvue reaffirmed its prior guidance for 2025 as well. The company still expects revenue to be down a low single-digit figure, compared to prior ranges of +1% to +3% and -1% to 1%. Adjusted earnings-per-share are still expected to be in a range of \$1.00 to \$1.05 compared to prior guidance of unchanged EPS.

Growth on a Per-Share Basis

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2030
EPS	---	---	---	---	---	---	---	---	\$1.29	\$1.14	\$1.03	\$1.19
DPS	---	---	---	---	---	---	---	---	\$0.40	\$0.81	\$0.83	\$0.96
Shares³	---	---	---	---	---	---	---	---	1,919	1,929	1,918	1,918

Johnson & Johnson produced annual earnings growth of 7% over the last decade as the company's diversification allowed it to be one of the more stable companies in the market place. Kenvue consists of just the consumer products businesses, which often produced the lowest levels of growth. Therefore, we expect that Kenvue will grow earnings-per-share by 3% annually through 2030.

¹ Estimated ex-dividend date.

² Estimated dividend payment date.

³ In millions of shares.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Kenvue Inc. (KVUE)

Updated December 1st, 2025 by Nathan Parsh

Johnson & Johnson's dividend growth streak of more than six decades is one of the longest in the market place. The company is both a Dividend King and a Dividend Aristocrat. We believe that penchant for dividend growth is in Kenvue's business DNA. The annualized dividend of \$0.83 per share represents a dividend yield of 4.8%, which is more than four times the average of the S&P 500 Index. We also note that this yield is well above Johnson & Johnson's 10-year average yield of 2.7% for additional context.

Valuation Analysis

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	Now	2030
Avg. P/E	---	---	---	---	---	---	---	---	16.0	18.9	16.8	14.0
Avg. Yld.	---	---	---	---	---	---	---	---	1.9%	3.8%	4.8%	5.8%

Shares of Kenvue have decreased 18.2% since our August 17th, 2025 report. The stock is trading at nearly 17 times expected earnings-per-share for 2025. For context, Johnson & Johnson shares have an average price-to-earnings ratio of close to 19 over the last decade. Countering the fact that Kenvue holds some of the industry leading brands with the fact that these products were the lower margin businesses within the parent company, we have a target price-to-earnings ratio of 14.0 for the stock. This implies a headwind from multiple contraction. Therefore, valuation could reduce annual returns by 3.6% through 2030.

Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2030
Payout	---	---	---	---	---	---	---	---	31%	71%	81%	81%

Johnson & Johnson has proven to be one of the most successful companies at navigating recessions. Though Kenvue no longer benefits from its parent company's diversification, we believe that it would prove equally effective at handling economic downturns. The company's products, such as Band-Aid and Tylenol, are needed regardless of the state of the economy as they deal directly with consumers' health and well-being. As trusted products, they would like continue to perform well even under adverse conditions.

Final Thoughts & Recommendation

Following third quarter results, Kenvue is projected to offer an annual return of 4.1% through 2030 compared to our prior estimate of 0.1%. This return stems from 3% earnings growth and a starting yield of 4.8%. offset by a valuation headwind. After decades as part of Johnson & Johnson, Kenvue became an independent entity early in 2023. The company has produced decent results in its infancy as a standalone company. While we find the legacy business to be recession-resistant and the yield to be generous, the total return profile remains unattractive at the current time. We reaffirm our five-year price target \$2 to \$17, but we continue to view shares of Kenvue as a hold. However, these projections will prove meaningless as long as the acquisition by Kimberly-Clark is approved.

Total Return Breakdown by Year



Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Kenvue Inc. (KVUE)

Updated December 1st, 2025 by Nathan Parsh

Income Statement Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Revenue	---	---	---	---	14,324	14,467	15,054	14,950	15,444	15,455
Gross Profit	---	---	---	---	7,662	7,848	8,419	8,220	8,643	8,959
Gross Margin	---	---	---	---	53.5%	54.2%	55.9%	55.0%	56.0%	58.0%
SG&A Exp.	---	---	---	---	5,198	4,956	5,484	5,767	6,141	6,329
D&A Exp.	---	---	---	---	709	746	731	644	627	622
Operating Profit	---	---	---	---	2,399	2,988	3,012	2,469	2,484	2,635
Operating Margin	---	---	---	---	16.7%	20.7%	20.0%	16.5%	16.1%	17.0%
Net Profit	---	---	---	---	1,435	(879)	2,031	1,455	1,664	1,030
Net Margin	---	---	---	---	10.0%	-6.1%	13.5%	9.7%	10.8%	6.7%
Free Cash Flow	---	---	---	---	2,709	3,168	39	2,150	2,699	1,335
Income Tax	---	---	---	---	685	(137)	894	454	526	385

Balance Sheet Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	---	---	---	---	---	29,177	27,929	27,358	27,851	25,601
Cash & Equivalents	---	---	---	---	---	618	740	1,170	1,382	1,070
Acc. Receivable	---	---	---	---	---	1,858	2,074	2,034	2,073	2,165
Inventories	---	---	---	---	---	1,685	1,702	2,189	1,851	1,591
Goodwill & Int.	---	---	---	---	---	21,936	20,511	19,038	18,890	17,317
Total Liabilities	---	---	---	---	---	10,821	7,530	16,361	16,640	15,933
Accounts Payable	---	---	---	---	---	1,579	1,827	1,821	2,489	2,254
Long-Term Debt	---	---	---	---	---	---	---	8,930	8,286	8,494
Total Equity	---	---	---	---	---	18,356	20,399	10,997	11,211	9,668
LTD/E Ratio	---	---	---	---	---	-	-	0.81	0.74	0.88

Profitability & Per Share Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Assets	---	---	---	---	---	7.1%	5.3%	6.0%	6.0%	3.9%
Return on Equity	---	---	---	---	---	10.5%	9.3%	10.7%	10.7%	9.9%
ROIC	---	---	---	---	---	10.5%	7.2%	8.4%	8.4%	5.5%
Shares Out.	---	---	---	---	---	---	---	1,919	1,919	1,929
Revenue/Share	---	---	---	7.58	7.66	7.97	7.91	8.35	8.35	8.04
FCF/Share	---	---	---	1.43	1.68	0.02	1.14	1.46	1.46	0.69

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.